Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.

@article{Fung1999EfegatranSA,
  title={Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.},
  author={Anthony Y. H. Fung and Gwendolen Lorch and Patrick A Cambier and Dominique Hansen and Bradley Titus and Jenny S. Martin and Jacqueline J Lee and Nathan R. Every and Alfred P. Hallstrom and Donna Stock-Novack and Joseph J Scherer and William D. Weaver},
  journal={American heart journal},
  year={1999},
  volume={138 4 Pt 1},
  pages={696-704}
}
BACKGROUND Previous clinical studies have shown that direct antithrombins can accelerate clot lysis after treatment with streptokinase in acute myocardial infarction (MI). Efegatran is a new direct antithrombin, which in experimental animals has been shown to enhance thrombolysis, reduce rate of reocclusion, and limit infarct size. This study was designed to compare the efficacy of efegatran plus streptokinase versus heparin plus accelerated tissue plasminogen activator (TPA) in coronary… CONTINUE READING